F. Hagemeister

发表

A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma

C. Fuller, M. Aristophanous, Qianghu Wang, 2019, Scientific Reports.

Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Limited CT studies in monitoring treatment of lymphoma.

M. Bernardino, F. Hagemeister, J. L. Thomas, 1982, AJR. American journal of roentgenology.

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Blood.

Early‐stage Hodgkin lymphoma outcomes after combined modality therapy according to the post‐chemotherapy 5‐point score: can residual pet‐positive disease be cured with radiotherapy alone?

O. Mawlawi, Y. Oki, E. Rohren, 2017, British journal of haematology.

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

L. Gordon, A. Younes, L. Kwak, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.

Michael L. Wang, Y. Oki, K. Young, 2016, The Lancet. Oncology.

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

J. Shah, J. Wood, P. Mclaughlin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of ifosfamide in the treatment of lymphomas.

F. Hagemeister, 1999, Leukemia & lymphoma.

Paclitaxel plus high‐dose cyclosphosphamide with G‐CSF support in patients with relapsed and refractory aggressive non‐Hodgkin's lymphoma

P. Mclaughlin, F. Cabanillas, A. Younes, 1998, British journal of haematology.

Treatment of small non-cleaved cell lymphoma in the adult.

F. Hagemeister, 1996, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 1999, Leukemia & lymphoma.

Gastric mucosa-associated lymphoid tissue lymphoma.

Mitchell R. Smith, F. Hagemeister, H. Brereton, 2010, Seminars in oncology.

Ultra–low‐dose radiotherapy for definitive management of ocular adnexal B‐cell lymphoma

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2018, Head & neck.

Ultra–low‐dose radiotherapy for definitive management of ocular adnexal B‐cell lymphoma

Michael L. Wang, Y. Oki, B. Esmaeli, 2017, Head & neck.

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.

Christine F. Wogan, Y. Oki, A. Milbourne, 2016, JAMA oncology.

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

D. Chihara, C. Cheah, R. Champlin, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

Michael L. Wang, Shaojun Zhang, Linghua Wang, 2018, British journal of haematology.

Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

J. Winter, M. Piris, W. Tam, 2021, Blood Cancer Journal.

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

P. Mclaughlin, J. Manning, L. Medeiros, 2003, Cancer.

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma

Michael L. Wang, Y. Oki, H. Kantarjian, 2018, Cancer.

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

C. Cheah, L. Fayad, S. Neelapu, 2015, Haematologica.

transplantation strategy in mantle cell lymphoma Mature results of the M. D. Anderson Cancer Center risk-adapted

L. Medeiros, C. Tam, U. Popat, 2013 .

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.

Y. Oki, E. Shpall, A. Younes, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.

É. Oksenhendler, K. Young, Z. Xu-Monette, 2020, The oncologist.

EOE-13 in the detection of hepatosplenic lymphoma.

R. Fisher, M. Bernardino, J. Doppman, 1982, Radiology.

Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

Maria A. Rodriguez, C. Flowers, L. Fayad, 2020, Leukemia & lymphoma.

Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.

S. Jagannath, S. Tucker, F. Cabanillas, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.

É. Oksenhendler, K. Young, Z. Xu-Monette, 2022, American journal of cancer research.

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Michael L. Wang, Shaojun Zhang, Linghua Wang, 2019, Blood.

Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center.

Michael L. Wang, C. Tam, U. Popat, 2007 .

A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Michael L. Wang, Y. Oki, P. Mclaughlin, 2004 .

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

L. Gordon, A. Younes, L. Kwak, 2009 .

Rituximab in indolent lymphoma: the single-agent pivotal trial.

P. Mclaughlin, F. Hagemeister, F. Hagemeister, 1999, Seminars in oncology.

LYMPHOID NEOPLASIA Assessment of CD37 B-cell antigen and cell of origin signi ﬁ cantly improves risk prediction in diffuse large B-cell lymphoma

J. Byrd, W. Choi, J. Winter, 2016 .

Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy.

Christine F. Wogan, Y. Oki, Y. Nieto, 2018, International journal of radiation oncology, biology, physics.

Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.

N. Ueno, K. Cleary, B. Andersson, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: the M. D. Anderson experience.

S. Jagannath, F. Cabanillas, J. Spinolo, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma.

Y. Oki, E. Shpall, Y. Nieto, 2018, International journal of radiation oncology, biology, physics.

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

P. Mclaughlin, J. Manning, F. Cabanillas, 2000, Bone Marrow Transplantation.

High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis.

E. Estey, H. Kantarjian, P. Mclaughlin, 1993, Leukemia & lymphoma.

Are alkylating agents a necessary component in the therapy of Hodgkin's disease.

F. Hagemeister, 1993, Leukemia & lymphoma.

Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)

Michael L. Wang, P. Jain, R. Kanagal-Shamanna, 2018, British journal of haematology.

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Michael R. Green, Shaojun Zhang, Guangchun Han, 2020, Nature Medicine.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Experience with 9-Cis Retinoic Acid in Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma

P. Mclaughlin, F. Cabanillas, M. Cristofanilli, 2000, Leukemia & lymphoma.

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.

H. Kantarjian, J. Cortes, F. Cabanillas, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Shaojun Zhang, Guangchun Han, Linghua Wang, 2020, Nature Medicine.

Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas.

F. Cabanillas, P. Allen, F. Hagemeister, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary C utaneous N on-Hodgkin's L ymphoma o f A nn A rbor Stage I : P referential C utaneous R elapses b ut H igh C ure Rate W ith D oxorubicin-Base d T herapy

P. Mclaughlin, J. Cox, F. Cabanillas, 2001 .

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.

Y. Oki, F. Turturro, Y. Nieto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma

J. Cox, F. Cabanillas, B. Andersson, 2004, Bone Marrow Transplantation.

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.

R. Davis, Y. Oki, F. Turturro, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.

P. Thall, Y. Oki, E. Shpall, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.

S. Jagannath, F. Cabanillas, J. Spinolo, 1993, Leukemia & lymphoma.

Causes of death in breast cancer a clinicopathologic study

A. Buzdar, G. Blumenschein, F. Hagemeister, 1980, Cancer.

Calcitriol Production in Hypercalcemic and Normocalcemic Patients with Non-Hodgkin Lymphoma

F. Cabanillas, J. Seymour, F. Hagemeister, 1994, Annals of Internal Medicine.

Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial

Jeffrey E. Lee, R. Winn, Yu Shen, 1999, Annals of Internal Medicine.

Hodgkin's Disease in Patients Infected with Human Immunodeficiency Virus: Frequency, Presentation and Clinical Outcome

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Leukemia & lymphoma.

Mantle Cell Lymphoma: Non-Myeloablative Versus Dose-intensive Therapy

F. Hagemeister, 2003, Leukemia & lymphoma.

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

H. Kantarjian, F. Cabanillas, A. Younes, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2000, Leukemia & lymphoma.

Outcome of Hodgkin's disease in elderly patients

F. Cabanillas, F. Hagemeister, F. Hagemeister, 1995, Hematological oncology.

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Michael L. Wang, J. Byrd, W. Choi, 2016, Blood.

Assessment of CD 37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma

Yong, Li, John, 2016 .

Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data.

S. Jagannath, S. Tucker, W. Velasquez, 1989, Blood.

A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma

C. Fuller, M. Aristophanous, Qianghu Wang, 2019, Scientific Reports.

Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China

Michael L. Wang, S. Parmar, E. Shpall, 2017, Oncotarget.

A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma.

F. Hagemeister, I. Khouri, D. Przepiorka, 1995, Leukemia & lymphoma.

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

P. Mclaughlin, F. Cabanillas, A. Younes, 1994, Investigational New Drugs.

Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2003, Cancer.

Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL).

P. Mclaughlin, D. Schenkein, L. Fayad, 2004, Journal of Clinical Oncology.

Follicular large cell lymphoma: An aggressive lymphoma that often presents with favorable prognostic features

Maria A. Rodriguez, P. Mclaughlin, F. Cabanillas, 1999 .

Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?

F. Cabanillas, S. Strom, L. Medeiros, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

A. Zelenetz, P. Mclaughlin, L. Fayad, 2010 .

Hyper-CVAD P rogram i n B urkitt's-Type A dult A cute Lymphoblastic L eukemia

H. Kantarjian, J. Cortes, F. Cabanillas, 1999 .

Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.

Christine F. Wogan, Y. Oki, F. Turturro, 2015, International journal of radiation oncology, biology, physics.

LENALIDOMIDE AND OBINUTUZUMAB WITH CHOP FOR NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: PHASE I/II RESULTS

Y. Oki, K. Young, L. Fayad, 2017 .

Paclitaxel activity for the treatment of non‐Hodgkin's lymphoma: final report of a phase II trial

R. Kurzrock, P. Mclaughlin, L. North, 1997, British journal of haematology.

Erratum to: Ultra–low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma (Head Neck, (2017), 39, (1095–1100), 10.1002/hed.24717)

Michael L. Wang, Y. Oki, B. Esmaeli, 2018 .

New approaches to management of Hodgkin's disease designed to minimize long-term sequelae

W. Velasquez, L. Fuller, S. Woo, 1989 .

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

D. Chihara, C. Cheah, R. Champlin, 2015 .

Recovery of sperm production following radiation therapy for Hodgkin's disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP).

L. Fuller, J. Cox, M. Meistrich, 2000, International journal of radiation oncology, biology, physics.

Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells

Linghua Wang, Koichi Takahashi, J. Westin, 2023, Cell reports. Medicine.

Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology.

F. Hagemeister, 1993, Leukemia & lymphoma.

Hodgkin's disease variant of Richter's syndrome: experience at a single institution.

J. Manning, F. Cabanillas, M. Keating, 1996, Leukemia & lymphoma.

Further follow-up of results of treatment in 90 laparotomy-negative stage I and II Hodgkin's disease patients: significance of mediastinal and non-mediastinal presentations.

L. Fuller, L. North, H. Madoc‐Jones, 1980, International journal of radiation oncology, biology, physics.

Mycosis fungoides with focal segmental glomerular sclerosis and nephrotic syndrome.

M. Duvic, F. Hagemeister, F. Hagemeister, 1998, Journal of the American Academy of Dermatology.

Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy.

P. Mclaughlin, F. Cabanillas, J. Cox, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Michael L. Wang, Y. Oki, D. Podoloff, 2006 .

Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China

Michael L. Wang, S. Parmar, E. Shpall, 2017, Oncotarget.

Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies.

L. Fuller, J. Cox, B. Brown, 1997, International journal of radiation oncology, biology, physics.

The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone

P. Mclaughlin, F. Cabanillas, M. Overman, 2007 .